Table 3 Frequencies of immunoglobulins against HEV and clinical outcomes in the two control groups (healthy controls and HIV-monoinfected patients) and HIV/HCV-coinfected patients.
From: Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
IgM anti-HEV Ab. | IgG anti-HEV Ab. | Acute hepatitis E | Resolved hepatitis E | Exposure to HEV | |
|---|---|---|---|---|---|
Healthy controls | 0 (0%) | 2 (6.7%) | 0/30 (0%) | 2/30 (6.7%) | 2/30 (6.7%) |
HIV-monoinfected patients | 3 (8.3%) | 4 (11.1%) | 3/36 (8.3%) | 3/36 (8.3%) | 6/36 (16.7%) |
HIV/HCV-coinfected patients | 10 (5.1%) | 38 (19.2%) | 10/198 (5.1%) | 34/198 (17.2%) | 44/198 (22.2%) |
p-value (HC vs. HIV) | 0.505 | 0.845 | 0.514 | 0.760 | 0.389 |
p-value (HC vs. HIV/HCV) | 0.710 | 0.127 | 0.721 | 0.230 | 0.082 |
p-value (HIV vs. HIV/HCV) | 0.692 | 0.295 | 0.692 | 0.277 | 0.560 |
